Mouse Anti-Tetanus Toxoid IgG ELISA kit

Sample

serum, plasma

Species Reactivity

Mouse

Detection Method

iELISA

Intended Use

The Mouse Anti-Tetanus Toxoid IgG ELISA Kit detects and quantifies tetanus toxoid/toxin-specific IgG in mouse serum or plasma of vaccinated or immunized animals. This immunoassay is suitable for:
1. Determining immune status relative to non-immune controls;
2. Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
3. Qualifying and/or standardizing vaccine batches and protocols.

Contents of Kit

1. Wash Solution Concentrate (100×), 10ml
2. Sample Diluent Concentrate (20×), 10ml
3. Anti-Mouse IgG-HRP Conjugate Concentrate (100×), 0.15ml
4. Tetanus Toxoid Microwell Strip Plate, 8-well strips (12). Coated with tetanus toxoid, and post-coated with stabilizers.
5. Anti-Tetanus Toxoid Calibrators. 0.65ml each. 10 U/ml, 25 U/ml, 50 U/ml, 100 U/ml. Four (4) vials, each containing anti-tetanus toxoid levels in arbitrary activity Units; diluted in buffer with protein, detergents and antimicrobial as stabilizers. The calibrators are dilutions of antibody reactive to tetanus toxoid. Values are assigned as arbitrary anti-tetanus toxoid activity units.
6. Anti-Tetanus Positive Control, 0.65 ml. Anti-tetanus toxoid Ab, in buffer with protein, detergents and antimicrobial. Value range on label.
7. Low NSB Sample Diluent, (Reduces non-specific binding), 30 ml. Buffer with protein, detergents and antimicrobial as stabilizers. Use as is for sample dilution.
8. TMB Substrate, 12 ml. Chromogenic substrate for HRP containing TMB and peroxide.
9. Stop Solution, 12 ml. Dilute sulfuric acid.

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.

Sensitivity

The tetanus toxoid coating level, HRP conjugate concentration and Low NSB Sample Diluent are optimized to differentiate anti-tetanus toxoid IgG from background (non-antibody) signal with mouse serum samples diluted 1:100

General Description

Tetanus, a neurotoxic disease resulting in severe muscular spasm, is caused by Clostridium tetani bacteria. Tetanus toxin, a protein exotoxin produced only by C. tetani, is central to tetanus pathogenesis. Vaccination with the inactivated toxin (toxoid) elicits high levels of protection from the disease. The toxoid also acts as an adjuvant to boost immune responses to other antigens when combined in a vaccine, either mixed or covalently conjugated. Vaccines for tetanus are available in combination with other vaccines, e.g., pertussis, diphtheria, H. influenza b, hepatitis & polio. Monitoring the efficacy of vaccines by determining the anti-tetanuslevels in the host, including for clinical trials using new formulation of vaccines, is often required.